Skip to main content
. 2014 Apr 18;5(9):2778–2791. doi: 10.18632/oncotarget.1916

Figure 7. A549 or HeLa sensitivity to cisplatin (8 or 4 microM, respectively) before (A and C) and after (B and D) IDO induction.

Figure 7

Results were obtained from independent measurements of proliferation of 3 A549 or HeLa clonal populations harbouring control scrambled shRNA and 3 harboring anti-IDO shRNA. Bars represent the means of 3 independent measurements (n=3 for each measurement) ± SEM (*p≤0.05).